Getty Images
According to a recent Reuters article, the FDA declined to approve two cancer treatments developed in China. The drugs in question are Hutchmed’s pancreatic cancer treatment and a throat cancer medicine developed by Junshi and Coherus. Single-country trials are responsible for the rejection of the former, while manufacturing issues held up the latter.